Patent details

300851 Product Name: Combinatie van: - rilpivirine of een therapeutisch equivalente vorm daarvan zoals beschermd door het basisoctrooi, zoals een farmaceutisch aanvaardbaar zout van rilpivirine, waaronder het hydrochloridezout van rilpivirine; - emtricitabine; en - tenofoviralafenamide of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder tenofoviralafenamidefumaraat.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300851
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1663240
Status:
Withdrawn
Application number:
300851
Procedural language:
Dutch
First Applicant Residence Country:
Ireland (IE)

Marketing Authorization

Marketing Authorization Number:
EU/1/16/1112
Marketing Authorization Type:
EEA
Marketing Authorization Date:
23/06/2016
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
20/12/2016
First Marketing Authorization date:
23/06/2016
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
23/12/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
04/10/2021
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
23/12/2016
 
 

 

Name:
Janssen Sciences Ireland UC
Address:
Eastgate Village, Eastgate, LITTLE ISLAND, COUNTY CORK, Ireland (IE)

Agent

Name:
ir. F.A. Geurts c.s.
From:
23/12/2016
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
40/21
Publication date:
22/12/2021
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
52/16
Publication date:
28/12/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
04/10/2021 SPC Documents Withdrawal SPC 1 PDF /9/2/3/8/1/0800118329/docs/300851_2_supplprotectioncertificate20211004112757405.pdf
04/10/2021 Outgoing Correspondence Letter confirmation withdrawal 1 PDF /9/2/3/8/1/0800118329/docs/300851_6_438147l193.pdf
01/07/2021 Outgoing Correspondence Letter to applicant 2 PDF /9/2/3/8/1/0800118329/docs/300851_4_419339l173.pdf
29/06/2017 SPC Documents Mail SPC 2 PDF /9/2/3/8/1/0800118329/docs/300851_3_supplprotectioncertificate20200421035638333.pdf
11/05/2017 SPC Documents Mail SPC 3 PDF /9/2/3/8/1/0800118329/docs/300851_0_supplprotectioncertificate20200421035459286.pdf
02/02/2017 Outgoing Correspondence Letter to applicant 3 PDF /9/2/3/8/1/0800118329/docs/300851_9_outgoingcorrespondence20170203110658018.pdf
27/12/2016 Outgoing Correspondence Confirmation receipt request 1 PDF /9/2/3/8/1/0800118329/docs/300851_10_106637l174.pdf
20/12/2016 SPC Documents Annex SPC 1 PDF /9/2/3/8/1/0800118329/docs/300851_1_supplprotectioncertificate20200421035120270.pdf
20/12/2016 SPC Documents Accompanying letter SPC 1 PDF /9/2/3/8/1/0800118329/docs/300851_5_supplprotectioncertificate20210406025925373.pdf
20/12/2016 SPC Documents Marketing Authorization SPC 3 PDF /9/2/3/8/1/0800118329/docs/300851_7_supplprotectioncertificate20161222022443658.pdf
20/12/2016 Application Form First filed application form 3 PDF /9/2/3/8/1/0800118329/docs/300851_8_applicationform20161222022443373.pdf
20/12/2016 SPC Documents Summary of the characteristics of the product 33 PDF /9/2/3/8/1/0800118329/docs/300851_11_supplprotectioncertificate20161222022443750.pdf